Ultimately, our findings suggest that the future of KRAS inhibition lies in exploiting this universal architecture, where modular hydrogen bonding, aromatic stacking, and network-level restructuring combine to deliver potent, durable, and mutation-resilient targeting of one of cancer’s most persistent drivers. This evidence concerns the gene KRAS and cancer.